For assets in the preclinical to Phase 2 space evaluating the opportunity and planning the best development path to patient and market becomes a priority. The Phetairos POEM group can help to maximise the value of assets by providing an integrated view of the therapeutic area landscape, the competition, the development options and challenges, the regulatory path, and commercial considerations and risks. Additionally for those looking to acquire or license assets we can provide Due Diligence services with full valuation, deal terms, and legal and IP guidance.